- LumiraDx (NASDAQ:LMDX) has received emergency use approval by India’s Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test.
- The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
- The test is available in the U.S. and Europe under Emergency Use Authorization.
- The LumiraDx SARS-CoV-2 Antigen test is a microfluidic test run on the LumiraDx point of care Platform, which scales down. It integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point of care instrument.
- Related content: Benzinga’s Full FDA Calendar.
- Price Action: LMDX shares are up 13.20% at $9.54 during the market session on the last check Wednesday.
Regulus Therapeutics Q3 EPS $(0.10) Misses $(0.08) Estimate
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 150 percent decrease over losses of $(0.04) per share from
